# Jade Biosciences, Inc.: overview JBIO · Nasdaq · CIK 1798749 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/jbio.md) · [Financials](/companies/jbio/financials.md) · [Filings](/companies/jbio/filings.md) · [Insiders](/companies/jbio/insiders.md) Revenue is not reported in this company’s XBRL financial statements. ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(5.16)](/filings/0001193125-25-281525.md) | not reported | [(12.10)](/filings/0001193125-26-212088.md) | [(0.86)](/filings/0001193125-26-341242.md) | [(0.48)](/filings/0001193125-25-281525.md) | not reported | [(0.57)](/filings/0001193125-26-212088.md) | [(0.76)](/filings/0001193125-26-341242.md) | | Free cash flow | $m | not reported | not reported | not reported | not reported | [(22.2) d](/filings/0001193125-25-281525.md) | [(33.7) d](/filings/0001193125-26-096550.md) | not reported | not reported | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 12-month figure less the 9-month figure; 6-month figure less the 3-month figure; 9-month figure less the 6-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(1.87)](/filings/0001798749-23-000015.md) | [(2.10)](/filings/0001798749-24-000015.md) | [(2.87)](/filings/0001558370-25-003750.md) | [(2.44)](/filings/0001558370-25-003750.md) | [(3.19)](/filings/0001193125-26-096550.md) | | Free cash flow | $m | [(27.6)](/filings/0001798749-23-000015.md) | [(39.3)](/filings/0001798749-24-000015.md) | [(56.9)](/filings/0001558370-25-003750.md) | not reported | [(94.9)](/filings/0001193125-26-096550.md) | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/jbio/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [FMR LLC](/funds/315066.md) | 2026-06-30 | $202.8m | 9,126,877 | | Added +2,041,454 | | [Jupiter Topco LLC](/funds/2146052.md) | 2026-06-30 | $139.4m | 6,273,262 | | Not compared | | [Fairmount Funds Management LLC](/funds/1802528.md) | 2026-06-30 | $101.2m | 4,553,494 | | Unchanged | | [RA CAPITAL MANAGEMENT, L.P.](/funds/1346824.md) | 2026-06-30 | $81.6m | 3,671,083 | | Unchanged | | [Venrock Adviser, LLC](/funds/1615982.md) | 2026-06-30 | $71.6m | 3,220,364 | | Unchanged | | [Bellevue Group AG](/funds/1674546.md) | 2026-06-30 | $67.9m | 3,057,996 | | Reduced −443,506 | | [Paradigm Biocapital Advisors LP](/funds/1855655.md) | 2026-06-30 | $63.5m | 2,857,405 | | New +2,857,405 | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $62.2m | 2,801,451 | | Added +487,502 | | [FRANKLIN RESOURCES INC](/funds/38777.md) | 2026-06-30 | $62.0m | 2,792,080 | | New +2,792,080 | | [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $51.9m | 2,335,285 | | Added +1,679,595 | ## Recent filings [All 504 filings](/companies/jbio/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-09-30 | 07:13 ET | [8-K](/filings/0001193125-26-408287.md) | 8.01 Other events | 0001193125-26-408287 | | 2026-08-10 | 07:21 ET | [10-Q](/filings/0001193125-26-341242.md) | Quarterly report, period 2026-06-30 | 0001193125-26-341242 | | 2026-08-10 | 07:13 ET | [8-K](/filings/0001193125-26-341229.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-341229 | | 2026-07-01 | 16:41 ET | [8-K](/filings/0001193125-26-292704.md) | 1.01 Entry into a material agreement | 0001193125-26-292704 | | 2026-06-26 | 07:15 ET | [8-K](/filings/0001193125-26-283906.md) | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-283906 | | 2026-06-11 | 16:28 ET | [8-K](/filings/0001193125-26-267640.md) | 5.03 Amendment to articles or bylaws; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001193125-26-267640 | | 2026-06-09 | 17:30 ET | [SCHEDULE 13D/A](/filings/0001104659-26-071942.md) | Ownership report, active investor, amended | 0001104659-26-071942 | | 2026-06-04 | 17:09 ET | [8-K](/filings/0001193125-26-257733.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-257733 | | 2026-06-01 | 07:55 ET | [8-K](/filings/0001193125-26-249763.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-249763 | | 2026-05-07 | 16:27 ET | [10-Q](/filings/0001193125-26-212088.md) | Quarterly report, period 2026-03-31 | 0001193125-26-212088 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-096550.md), filed Mar 6, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1798749 - Tickers: JBIO - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: DE - Filer category:
Emerging growth company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:48 ET. No prices; not investment advice.